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Abstract
This article presents a review of the literature assessing the effectiveness and safety of sulodexide in the proph-
ylaxis of deep vein thrombosis and treatment of chronic venous disease. It was demonstrated that sulodexide 
is effective and safe in the prophylaxis of deep vein thrombosis and treatment of chronic venous insufficiency 
with ulcers. Sulodexide is characterized by low frequency of bleeding complications. 
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Sulodexide is a naturally occurring glycosaminoglycan 
obtained from pig intestine. Clinical uses of sulodexide 
include prevention of venous thromboembolic disease 
(VTD) recurrence, treatment of chronic venous disease 
(CVD) and moderate chronic arterial occlusive disease 
of the lower limbs. In this publication, we analyze the 
scientific evidence regarding effectiveness and safety of 
sulodexide in the treatment of VTD and CVD. 
In order to understand the pharmacological func-
tions of sulodexide, it is necessary to know the structure 
of vascular endothelium. The surface of tunica intima 
of those vessels is lined by glycocalyx, which is com-
posed of proteoglycans, hyaluronic acid, glycoproteins, 
and white cells absorbed on its surface. Glycocalyx 
plays a number of important roles: regulates vascular 
permeability, controls their tone, determines inter-
action of vascular wall with leukocytes and thrombo-
cytes, and regulates response to vascular stress. The 
above-mentioned mechanisms are decisive for proper 
blood flow, which is directly related to anticoagulant 
and pro-fibrinolytic action of glycocalyx [1, 2]. Serum 
antithrombin (AT), which binds to heparin sulfate con-
tained in proteoglycans of the glycocalyx, is the key to 
its anticoagulant effect. Such a combination changes 
spatial structure of AT. Conformational changes of an-
tithrombin are responsible for its anticoagulant action: 
they potentiate anticoagulant effect and inhibition of 
several active coagulation factors [2]. 
Sulodexide contains 80% of fast moving heparin 
(FMH) and 20% of dermatan sulfate (free fraction) [3]. 
Structure of FMH resembles that of unfractionated 
heparin. Its biological and pharmacological effects on 
the coagulation cascade are also similar to heparin [3]. 
Dermatan sulfate contains fewer sulfate residues, 
thus exhibiting weaker anticoagulant effect. Mean 
molecular weight of dermatan sulfate (free fraction) 
is several times greater than FMH. The anticoagulant 
effect of dermatan sulfate involves inhibition of active 
coagulation factor II (thrombin) through affinity to 
heparin cofactor II, which is a natural inhibitor of this 
factor [4]. 
Sulodexide is packaged in a parenteral form (am-
poules), which can be administered intravenously and 
intramuscularly, as well as in the form of capsules for 
oral administration.
Bioavailability of oral preparation of sulodexide 
reaches 40% and maximal concentration is reached 
after four hours from capsule ingestion. Sulodexide 
exhibits significant affinity to endothelium and glycoc-
alyx — higher than to the circulating proteins (which 
is why it affects global coagulation parameters only to 
a minimal extent). When administered orally, it does 
not affect the activated partial thromboplastin time 
(aPTT) [5].
Sulodexide is metabolized in the liver and excreted 
through the kidneys [5]. 
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The effect of sulodexide on the coagulation system 
is less than unfractionated heparin or low molecular 
weight heparins because its pharmacological action is 
contained mainly to the glycocalyx. 
It should be emphasized that sulodexide accelerates 
spontaneous fibrinolysis of intravascular thrombi by 
increasing the concentration of plasminogen activator 
(tPA) and inhibiting tissue plasminogen inhibitor (PAI) [6]. 
Sulodexide also reduces platelet aggregation [7]. 
The anti-inflammatory action of sulodexide con-
stitutes an important biological effect directly related 
to its clinical effects [7]. It is related directly to the 
inhibition of thrombin activity and thrombogenesis 
and indirectly to the inhibition of leukocyte activity and 
their adhesion to endothelium, reduction of cytokine 
release and platelet aggregation [7]. Sulodexide exhibits 
an inhibitory effect on the macrophage, heparanase and 
metalloproteinase activity ]8]. 
However, the most important and central effect 
of sulodexide involves the protection and repair of 
endothelium and glycocalyx by supplying glycosamino-
glycans to its structures [8]. 
It should be mentioned that sulodexide also affects 
lipid metabolism. It reduces triglyceride levels and in-
creases HDL concentrations. Sulodexide also reduces 
blood viscosity [8].
The half-life of sulodexide is significantly longer than 
in unfractionated heparin. In contrast to heparins, oral 
administration is feasible [5]. 
The most important are the biological effects of 
sulodexide, which translate into clinical effects [1–5]. 
These effects include anticoagulant action within arter-
ies and veins, profibrinolytic action, anti-inflammatory 
effect, protection of the endothelium and glycocalyx, 
and regulation of the vascular tone [8]. 
Effectiveness and safety of sulodexide  
in the prevention of venous  
thromboembolic disease (VTD)
Scientific evidence regarding the effectiveness and ex-
cellent safety profile of sulodexide in the prophylaxis 
(therapy) of deep vein thrombosis (DVT) recurrence is 
solid and translated into recommendations contained 
in the Polish guidelines [9–12]. 
The treatment of DVT consists of three phases: 
acute treatment phase, usually lasting 5–7 days (in 
patients treated with rivaroxaban this phase lasted 
21 days), long-term anticoagulation therapy lasting 3 
months, and chronic prophylaxis (therapy) of DVT 
recurrence, which lasts from several months to years, 
and may be indefinite in some patients [12]. 
Long-term, chronic anticoagulation prophylaxis 
(therapy) is indicated i.a. in patients with idiopathic DVT. 
In this group of patients, the risk of recurrence is only 
reduced when chronic prophylaxis (therapy) of DVT 
recurrence with anticoagulants is continued. The risk of 
DVT recurrence increases when anticoagulation stops 
and the probability of DVT recurrence is independent 
of the length of anticoagulation therapy [12].
Two elements play a fundamental role in chronic 
prophylaxis (therapy) of DVT recurrence: effective-
ness of anticoagulant agents measured as reduction in 
relative risk of DVT recurrence and safety of therapy, 
which is measured by the incidence of hemorrhagic 
complications, the most important of which are major 
bleedings requiring hospitalization — some of them be-
ing life-threatening. Sulodexide is characterized by great 
safety in the prophylaxis of DVT recurrence [11–13].
To a physician involved in the treatment of DVT, 
episodes of DVT recurrence, as well as, hemorrhagic 
complications constitute the most undesirable and 
critical elements of therapy. Therefore, the incidence 
of recurrences and the frequency of bleeding compli-
cations should be assessed simultaneously as a clinical 
net benefit when comparing different anticoagulation 
agents [13]. Unilateral comparison of the effectiveness 
or safety alone is flawed and may pose a threat to the 
patient’s outcome. Somewhat lower effectiveness of 
sulodexide in the prevention of DVT recurrence is 
compensated by an excellent safety profile [13]. 
Very high effectiveness and excellent safety profile 
of sulodexide in the prevention of DVT recurrence was 
demonstrated in the SURVET trial [11]. It was a mul-
ti-center, randomized, double-blind study comparing 
the effectiveness and safety of sulodexide versus pla-
cebo. The study included 615 patients who completed 
3–12 months of chronic anticoagulation therapy after 
an episode of DVT or pulmonary embolism (PE). Deep 
vein thrombosis was diagnosed in 92% and PE in 8% 
of patients included in the study. 
Sulodexide 2 × 2 capsules (2 × 500 LSU) or placebo 
were administered over a 2-year period together with 
compression therapy. 
The effectiveness of sulodexide, basing on the frequency 
of DVT recurrence and safety, was assessed as the frequen-
cy of hemorrhagic complications — major bleeding and 
clinically relevant bleeding complications other than major.
DVT recurrence took place in 4.9% of patients in 
the sulodexide group and in 9.7% of patients in the 
placebo group (HR 0.49; 95%CI 0.27–0.92; P = 0.02; 
after applying statistical methods of unification of popu-
lation HR = 0.45) within a 24-month follow-up period. 
There were no major bleeding complications in the 
group of patients receiving sulodexide as well as in the 
placebo group. Only two clinically significant bleeding 
complications other than major bleeding were observed 
in each group. 
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The SURVET trial corroborated an acceptable 
effectiveness of sulodexide in prevention of VTE recur-
rence among patients with DVT as well as an excellent 
therapeutic safety. Obtained results constitute the basis 
for recommending sulodexide in patients with a high 
risk of bleeding complications during DVT prophylaxis 
(therapy) [11, 12]. 
The two following studies assessing the effective-
ness of sulodexide in preventing DVT recurrence are 
of lesser clinical significance [9, 10]. 
The first one is a registry based on an analysis of 
405 patients diagnosed with DVT who have complet-
ed 6 months of anticoagulation therapy. Subsequently, 
patients were allocated to the control group (no antico-
agulation) and the group where patients received sulo-
dexide (2 × 1 capsule) for 24 months. Both groups did 
not differ with regard to demographics and presented 
a similar DVT location profile. The frequency of DVT 
recurrence reached 7.4% in the group receiving sulo-
dexide and 17.9% in the control group (P < 0.05) [9]. 
In another study, the effectiveness and safety of su-
lodexide was compared with vitamin K antagonists. The 
trial included 150 patients with proximal DVT. After the 
acute phase of therapy (patients received nadroparin 
and urokinase) patients were randomly assigned to 
one of 2 groups. In the first group acenocoumarin was 
used to keep INR in a range 2–3, while the other group 
received sulodexide. Follow-up continued for 3 months. 
No statistically significant differences were noted with 
regard to the incidence of VTE recurrence, while the 
frequency of bleeding complications was significantly 
higher in the group of patients receiving acenocoumarin 
(13% vs. 0%; P = 0.014) [10]. 
While summarizing the effectiveness and safety of 
sulodexide in prevention of VTE recurrence, it should 
be emphasized that this agent is characterized by ex-
cellent safety and acceptable efficacy. 
Administration of sulodexide  
in chronic venous disease
CVD is inherently associated with venous insufficiency, 
which constitutes the pathophysiological basis for the 
development of clinical manifestations of this disease: 
asymptomatic venous hypertension, varicose veins of 
the lower limbs, post-thrombotic syndrome and leg 
ulcers. 
Venous hypertension developed as a result of reflux 
due to underlying structural and functional abnor-
malities of the venous system plays a key role in the 
development of chronic venous insufficiency. Venous 
hypertension leads to dilatation of veins and devel-
opment of insufficiency of vein valves. Hemodynamic 
changes are transferred from macrocirculation to mi-
crocirculation. Increase in venous pressures is accom-
panied by changes in blood flow, disruption of laminar 
flow and leukocyte adhesion to vascular endothelium, 
as well as augmented release of proteolytic enzymes. 
Activated neutrophils and monocytes are sequestered 
in the vascular endothelium and neighboring tissues. 
As a result of the above-described mechanisms there 
is an increased release of inflammatory mediators: 
chemokines, cytokines, matrix metalloproteinases 
(MMPs), or transforming growth factor ß, from acti-
vated cells, contributing to the development and pro-
gression of inflammation. Chronic inflammation results 
in destruction of extracellular matrix and irreversible 
remodeling of venous vessels and valves. Disease pro-
gresses as a consequence of these processes, leading 
to the development of varicose veins and, in the long 
term, formation of skin lesions and ulcerations [14,15]. 
Sulodexide exhibits antiproteolytic effect by attenu-
ating the activity of metalloproteinases that are involved 
in extracellular matrix degradation and play a key role 
in the processes responsible for the development of 
chronic venous insufficiency. MMP activity is weakened 
by inhibition of proteolytic action and reduction of syn-
thesis. Sulodexide was also shown to inhibit the activity 
of macrophages by reducing the release of inflamma-
tory mediators, such as interleukin-1ß, interleukin-7, 
interleukin-8, interleukin-12, interleukin-17, MMP-9, 
and granulocyte and macrophage colony-stimulating 
factor (GM-CSF). In non-healing ulcers the acute phase 
markers hinder progression to the granulation phase 
and ulcer healing. Sulodexide decreases the expres-
sion of acute phase proteins in the ulcer, at the same 
time increasing the expression of granulation phase 
markers [14]. 
Literature concerning clinical effects of VTE treat-
ment with sulodexide is quite abundant and the results 
are consistent [16–23]. 
Two studies were devoted to the effect of sulodex-
ide on venous hypertension [16, 17]. 
One of them examined changes in microcirculation 
using capillary filtration coefficient measured with strain 
gauge pletysmography [16]. Thirty-six patients with 
VTE were included in the study and randomly allocated 
to the sulodexide or placebo group. After 30 and 
45 days of therapy with sulodexide capillary filtration 
coefficient was significantly reduced by almost half 
compared to baseline values, suggesting clinical efficacy 
of this agent in the treatment of microcirculation disor-
ders in the course of chronic venous insufficiency [16]. 
In another trial, 476 patients with CVD were 
analyzed using double-blind randomization [17]. Half 
of the patients were diagnosed with post-thrombotic 
syndrome and the other half had idiopathic varicose 
veins of the lower limbs. Patients were divided into 
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three groups with equal distribution of different forms 
of CVD. In the first group sulodexide in a daily dose of 
2 × 1 capsule (50 mg) was used, in the second — 2 × 
2 capsules (2 × 50 mg), and in the third group — 1 × 
4 capsules (1 × 100 mg) for 60 days. Effects of therapy 
were controlled by Doppler phlebotensiometry, which 
was performed before commencement of treatment, 
after 1 month and after 2 months. Venous pressure 
was measured in upright and supine position. Meas-
urements were performed on the great saphenous 
vein and posterior fibular vein. Therapeutic response 
(reduction in venous pressure) depended on the dose 
of sulodexide — the greatest response was noted in 
the group receiving 4 capsules (100 mg) per day re-
gardless of whether it was given in a single dose or in 
two doses. Side effects in the form of gastrointestinal 
disorders were observed in 10% of patients included 
in the study — these symptoms subsided after 72 hours 
and did not require discontinuation of treatment [17]. 
The goal of another four randomized studies was to 
assess the effectiveness of sulodexide in the treatment 
of venous ulcers [18–21]. Compression therapy was 
also used in all of those studies. 
In the first trial, the effectiveness of sulodexide in the 
treatment of venous ulcers larger than 2 cm was assessed 
using a double-blind technique [18]. Two hundred and 
thirty-five patients were included. Greater frequency of 
complete ulcer healing was observed in the group receiv-
ing sulodexide after 2 months of treatment compared to 
the control group (35% vs. 20.9; P = 0.018) and after 
3 months (52.5% vs. 32.7%; P = 0.004). Adverse effects 
occurred in 19% of patients in the sulodexide group, only 
4 of which were considered related to the drug [18]. 
In another study assessing the frequency of total 
ulcer healing after 2 months, results were based on 
the analysis of 94 patients [19]. In the sulodexide group 
healing was demonstrated in 58% of subjects compared 
to 36% in the placebo group (P = 0.03) [19]. 
In an analysis performed by Kucharzewski et al. 
the efficacy of sulodexide was demonstrated in the 
treatment of large venous ulcers (mean ulcer surface 
was 12.4 cm2) [20]. The study included 44 patients. 
After 7 weeks of sulodexide administration recovery 
was observed in 70% compared to 35% in the control 
group (P < 0.05) [20]. 
The last trial from this group was based on the anal-
ysis of 114 patients [21]. Ulcer healing was evaluated 
after a month of sulodexide use. Complete remission 
after 30 days was observed in 52.5% of patients from 
sulodexide group vs. 32% from the control group 
(P < 0.05) [21]. 
A meta-analysis of the above-mentioned studies 
showed that the NNT (number needed to treat) for 
complete healing was 4 [22]. 
Consistent results of the presented studies gained 
sulodexide a place in the recommendations of numer-
ous scientific societies (American College of chest 
Physicians, American Venous Forum and Society for 
Vascular Surgery) for pharmacological treatment of ve-
nous ulcers. Sulodexide has a high level of evidence for 
the treatment of venous ulcers (GRADE A) according 
to the guidelines for the management of chronic venous 
lower limb disorders published in the International 
Angiology in 2018 [23].
The utility of sulodexide in the prophylaxis of 
post-thrombotic syndrome was also evaluated based 
on a registry of 339 patients [24]. The incidence of the 
post-thrombotic syndrome after 60 months was lower 
in the group receiving sulodexide (12.2% vs. 19.5% in 
the standard treatment group and 12.2% vs. 23.5% in 
the aspirin group; P < 0.05 for both analyses).
It should be emphasized that sulodexide is regis-
tered for the treatment of symptomatic primary or 
secondary venous insufficiency. In a study encompassing 
450 patients with CVD evaluating the effects of the 
drug at a dose of 2 × 1 capsule/day for 3 months on 
objective and subjective symptoms as well as on the 
quality of life of studied subjects a statistically significant 
effect of the drug on: pain, redness, skin thickening, skin 
temperature, feeling of heavy legs, paresthesia, cramps, 
was demonstrated. The examined symptoms became 
reduced by over 60% (P < 0.0001). Also, the quality 
of life measured using CIVIQ survey was significantly 
improved [25]. 
In the previously cited clinical trial of 476 patients 
the effect of the drug on the attenuation of CVD symp-
toms, including reduction of leg edema, was demon-
strated [17]. The Society for Vascular Surgery and the 
American Venous Forum propose use of venoactive 
agents, including sulodexide, in addition to compres-
sion therapy in the treatment of patients with pain and 
edema due to CVD. 
In the conclusion of the section devoted to CVD the 
proven efficacy and safety of sulodexide in the treat-
ment of venous ulcers and symptoms of CVD should be 
once again emphasized. Prophylaxis of post-thrombotic 
syndrome is one of the areas of the potential application 
of this drug [24]. 
Two studies demonstrated that sulodexide inhibits 
growth factors responsible for fibrosis and angiogenesis 
[VEGF (vascular endothelial growth factor), TGF-beta 
(transforming growth factor)] [26, 27]. 
Conclusions
Based on the review of the literature we assessed 
the effectiveness and safety of sulodexide in the prophy-
laxis of deep vein thrombosis recurrence and treatment 
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of chronic venous disease. Sulodexide was proven ef-
fective and safe in preventing recurrence of deep vein 
thrombosis and effective in the treatment of venous 
ulcers as well as other forms of CVD. An immanent 
feature of sulodexide — very low frequency of hemor-
rhagic complications, should be especially emphasized. 
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